Principia Biopharma (PRNB) Knocks on Big Pharma’s Door
Principia Biopharma continued its impressive progress with its recent initial public offering on September 14, 2018. Principia Biopharma (Nasdaq: PRNB) has developed three drug candidates in immunology, central nervous system disorders, and oncology.
The company is utilizing 'Tailored Covalency,' its proprietary drug discovery platform, to discover new drugs that combine the dosing ability of an oral small molecule drug with the specificity of an antibody.
Standard small molecule drugs have a short duration of time that the drug binds to its target, called residence time, that require dosing regimens to maintain target concentration levels in the blood to get the desired result.
Principia has designed its drugs to remain bound to the target, and clear the body rapidly, to optimize residence time. According to the company this will minimize adverse effects while achieving the desired benefit.
PRN1008 is being developed for multiple autoimmune diseases. The Phase 2 study of PRN1008 for use in treating pemphigus, a chronic disorder that cause blisters and sores on the skin or mucous membranes, is forthcoming.
Principia has partnered with Sanofi SNY in an exclusive, global licensing agreement to develop and commercialize PRN2246 for multiple sclerosis. Sanofi paid Principia $40 million upfront and agreed to future milestone payments that have the potential to amount to $765 million on top of royalties.
The stock is down approximately 25% since its IPO which may be the result of post-IPO selloff and not a reflection of the company’s prospects. At $24.00 versus its opening day high of $32.65, Principia Biopharma might be occupying a price range opportunity for savvy investors.
IBB in downward trend: price dove below 50-day moving average on May 24, 2023
IBB moved below its 50-day moving average on May 24, 2023 date and that indicates a change from an upward trend to a downward trend. In of 40 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on May 24, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The 10-day moving average for IBB crossed bearishly below the 50-day moving average on May 26, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for IBB entered a downward trend on May 31, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in of 346 cases, the price rose further within the following month. The odds of a continued upward trend are .
IBB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
General Information
Category Health
IBB and
Correlation & Price change
A.I.dvisor indicates that over the last year, IBB has been closely correlated with IBBQ. These tickers have moved in lockstep 98% of the time. This A.I.-generated data suggests there is a high statistical probability that if IBB jumps, then IBBQ could also see price increases.
